Clients rely on Jeremy's first-chair trial skills to navigate high-stakes and bet-the-company patent and antitrust litigation. 


Jeremy offers nearly two decades' experience representing clients in life sciences patent and antitrust trials, PTAB proceedings and other complex litigation matters. A "Recognized Practitioner" by Chambers USA, he is peer rated by Martindale-Hubbell as "AV Preeminent"—its highest possible rating in legal ability and ethical standards, and described as an "excellent lawyer" with "very good trial skills," that is "dedicated to both his clients and the legal profession." Jeremy has twice been recognized as a "Top Forty under 40" professional (Hartford Business Journal and Connecticut Magazine.)

The combined damages at stake in matters that Jeremy has tried to a jury exceed several billion dollars. One Federal Judge after trial referred to Jeremy as "an evidentiary savant." Opposing counsel has noted how Jeremy is "quick on his feet," while clients have noted after cross-examination that he is a "game-changer."  And Jeremy's appellate victories include the seminal Gilead v. Natco case, where the Court of Appeals for the Federal Circuit upended over a century of double patenting law. In another oral argument, one judge stated on the record that Jeremy's argument "just made our heads explode."

Clients rely on Jeremy's unique ability to combine these skills with his chemical engineering background to reduce complex technology to simple, understandable concepts. Jeremy is also dedicated to the profession. He frequently lectures, is active in his community, and enjoys spending time with his five children.


Representing defendants in a multi-billion dollar jury trial

Presenting oral arguments at the Federal Circuit

Representing defendants in an antitrust jury trial

Representing plaintiffs in a medical device patent jury trial

Representing defendants in pharmaceutical patent trials

Representing patent owner at PTAB in an IPR trial

Representing senior party at PTO in an interference

Representing defendant in antitrust and class action litigation

News & Insights

Speaking Engagements

"Challenges Big Pharma Faces in Bringing Interchangeable Biologics to Market," Recent Developments in Health Care and Life Sciences Law Seminar, Stinson, December 2019

"Participating in Post-Grant Proceedings: Think you Know it All? Think Again," ACI Advanced Summit on Medical Device and MedTech Patents

ACI's 8th Annual Summit on Biosimilars

Advanced Summit on Life Sciences Patents

ACI Life Sciences Patents Conference

"Preparing for Patent Litigation," Centerforce IP Enforcement Conference, 2014


"How Fed. Circ. Views Obviousness-Type Double-Patenting," Law360, October 2015

"Rule Against Double Patenting Regains Lost Luster," The National Law Journal, September 2014

"Endless Possibilities for 3D Medical Devices," Intellectual Property Magazine, July 2014

"BIO, PhRMA ask Fed. Circ. To Revisit Double-Patent Ruling," Law360, July 2014

"A Recent Supreme Court Decision Made it Harder to Prove Induced Patent Infringement," Device Talk, July 2014

"A Recent Supreme Court Decision Made it Easier to Invalidate Vague Medical Device Patents," Device Talk, July 2014



Chambers USA, Recognized Practitioner, 2016-2018

Hartford Business Journal Top 40 Under 40, 2013

Connecticut Law Tribune New Leaders in the Law, 2012

Connecticut Magazine Top 40 Under 40, 2012


  • Connecticut
  • Illinois
  • New York
  • U.S. Court of Appeals for the Federal Circuit
  • U.S. Patent and Trademark Office
  • U.S. Supreme Court


Washington University – St. Louis, J.D., 1999

University of Missouri, B.S., ChE, 1996

Jump to Page

We use cookies on our website to improve functionality and performance, analyze website traffic and enable social media features. For more information, please see our Cookie Policy.